Need professional-grade analysis? Visit stockanalysis.com
$1.80B
N/A
105
N/A
Definium Therapeutics, Inc. (DFTX) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $22.68, up 0.98% from the previous close.
Over the past year, DFTX has traded between a low of $5.80 and a high of $22.68. The stock has gained 291.0% over this period. It is currently 291.0% above its 52-week low.
Definium Therapeutics, Inc. has a market capitalization of $1.80B.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
Side-by-side comparison against top Healthcare peers.